XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Lease Exit Liability
9 Months Ended
Sep. 30, 2016
Lease Exit Liability [Abstract]  
Lease Exit Liability
4. Lease Exit Liability

On July 16, 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.  During the three months ended June 30, 2016, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.  The Company will receive approximately $1.3 million in sublease payments over its term, which ends at the same time as the original lease in February 2018.  No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the three months ended June 30, 2016 and recorded an offset to research and development expenses of approximately $1.3 million in the same period.

Changes in the lease exit liability are as follows (in thousands):

Accrual balance at December 31, 2015
 
$
4,713
 
Principal payments and other adjustments (net of sublease receipts)
  
(2,473
)
Accrual balance at September 30, 2016
 
$
2,240